Making the Call in Alzheimer’s Disease

Series Overview

Alzheimer’s disease (AD) is a rapidly changing field, given the recent approval of antiamyloid monoclonal antibodies. Early diagnosis of mild cognitive impairment (MCI) and AD is critical to improving patient outcomes. Early cognitive testing often leads to a need for more intensive cognitive testing, imaging, and referral to a neurologist, who may order biomarker testing to confirm an AD diagnosis. The patient can then be evaluated to determine eligibility for an antiamyloid therapy. The clinic must also be prepared to offer these therapies, with identified protocols for administering treatment and managing adverse events.

Target Audience

This series is designed to address identified knowledge and practice gaps among neurology and primary care clinicians who manage patients with MCI or early AD.